Prokidney to participate in upcoming investor conferences

Winston-salem, n.c., nov. 11, 2022 (globe newswire) -- prokidney corp. (nasdaq: prok) (“prokidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (ckd), today announced that dr. tim bertram, chief executive officer, will participate in the following upcoming investor conferences:

PROK Ratings Summary

PROK Quant Ranking